Comparative Pharmacology
Head-to-head clinical analysis: MACROBID versus MACRODANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROBID versus MACRODANTIN.
MACROBID vs MACRODANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial acetyl-CoA carboxylase, interfere with bacterial cell wall synthesis, and damage bacterial DNA. It is bactericidal against a broad spectrum of gram-positive and gram-negative bacteria.
100 mg orally twice daily with food for 7 days.
100 mg orally twice daily for 5 days; for uncomplicated UTI. Route: oral. Frequency: twice daily.
None Documented
None Documented
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
20-60 minutes (prolonged in renal impairment, up to 8 hours in anuria)
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Renal: 30-40% unchanged, Hepatic metabolism: 60-70% to inactive metabolites, Fecal: <1%
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective